You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 25, 2025

Abbvie Endocrine Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for ABBVIE ENDOCRINE INC

ABBVIE ENDOCRINE INC has six approved drugs.

There are two US patents protecting ABBVIE ENDOCRINE INC drugs.

There are thirty-five patent family members on ABBVIE ENDOCRINE INC drugs in twenty-eight countries.

Summary for Abbvie Endocrine Inc
International Patents:35
US Patents:2
Tradenames:3
Ingredients:1
NDAs:6

Drugs and US Patents for Abbvie Endocrine Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Endocrine Inc LUPRON DEPOT-PED KIT leuprolide acetate POWDER;INTRAMUSCULAR 020263-007 Aug 15, 2011 RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020517-003 Jun 17, 2011 RX Yes Yes 8,921,326 ⤷  Try for Free Y ⤷  Try for Free
Abbvie Endocrine Inc LUPRON DEPOT-PED KIT leuprolide acetate POWDER;INTRAMUSCULAR 020263-006 Jan 21, 1994 RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020011-002 Oct 26, 1995 RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Abbvie Endocrine Inc LUPRON leuprolide acetate SOLUTION;SUBCUTANEOUS 019010-001 Apr 9, 1985 DISCN Yes No ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Abbvie Endocrine Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Endocrine Inc LUPRON DEPOT-PED KIT leuprolide acetate POWDER;INTRAMUSCULAR 020263-002 Apr 16, 1993 4,728,721 ⤷  Try for Free
Abbvie Endocrine Inc LUPRON DEPOT-PED KIT leuprolide acetate POWDER;INTRAMUSCULAR 020263-004 Apr 16, 1993 6,036,976 ⤷  Try for Free
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020517-002 May 30, 1997 4,954,298 ⤷  Try for Free
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020708-001 Mar 7, 1997 5,814,342 ⤷  Try for Free
Abbvie Endocrine Inc LUPRON DEPOT-PED KIT leuprolide acetate POWDER;INTRAMUSCULAR 020263-003 Apr 16, 1993 5,476,663 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: AbbVie Endocrine Inc – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, AbbVie Endocrine Inc stands out as a formidable player, particularly in the endocrinology drugs market. This comprehensive analysis delves into AbbVie's market position, strengths, and strategic insights, offering a panoramic view of the company's competitive landscape.

AbbVie's Market Position in the Endocrinology Drugs Sector

AbbVie has carved out a significant niche in the endocrinology drugs market, which is projected to reach a staggering USD 78.0 billion by 2033, growing at a CAGR of 8.4%[1]. This robust growth trajectory presents both opportunities and challenges for AbbVie as it navigates the competitive landscape.

Market Share and Revenue

While specific market share data for AbbVie's endocrinology segment isn't directly available, we can glean insights from the company's overall performance. AbbVie's diverse product portfolio and strategic acquisitions have positioned it as a key player in the pharmaceutical industry, with a strong presence in immunology and oncology that complements its endocrinology offerings.

Global Footprint

AbbVie's global reach is a significant asset in the endocrinology drugs market. With operations spanning multiple countries, the company can tap into diverse markets and leverage regional opportunities. This global presence is particularly crucial in the endocrinology sector, where patient needs and regulatory landscapes vary significantly across regions.

AbbVie's Competitive Strengths in Endocrinology

Robust Product Portfolio

AbbVie's strength in endocrinology stems from its diverse range of products addressing various endocrine disorders. While specific endocrinology products aren't detailed in the provided information, the company's overall approach to maintaining a strong and varied product line is evident.

Research and Development Focus

AbbVie's commitment to innovation is reflected in its substantial R&D investments. With approximately 90 compounds in various stages of clinical development[1], the company is well-positioned to introduce new endocrinology treatments and maintain its competitive edge.

"AbbVie's strategic focus on innovation is evident from its investment in research and development, boasting approximately 90 compounds in various stages of development."[1]

Strategic Acquisitions and Partnerships

AbbVie's growth strategy includes strategic acquisitions and partnerships that enhance its endocrinology portfolio. For instance, the acquisition of Allergan in 2020 diversified AbbVie's product offerings and strengthened its position in various therapeutic areas, potentially including endocrinology.

Market Dynamics and Competitive Landscape

Key Market Drivers

Several factors are propelling the endocrinology drugs market forward:

  1. Rising prevalence of endocrine disorders
  2. Aging global population
  3. Technological advancements in drug delivery systems
  4. Increasing focus on personalized medicine

Competitive Intensity

The endocrinology drugs market is highly competitive, with several major pharmaceutical companies vying for market share. AbbVie faces competition from industry giants such as Novo Nordisk, Eli Lilly, and Sanofi, among others. Each company brings its unique strengths and product offerings to the table, creating a dynamic and challenging competitive environment.

AbbVie's Strategic Initiatives in Endocrinology

Innovation and Pipeline Development

AbbVie's strategy in endocrinology is closely tied to its overall approach to innovation. The company's robust pipeline, spanning various therapeutic areas, likely includes promising endocrinology candidates. This focus on developing new treatments is crucial for maintaining a competitive edge in the rapidly evolving pharmaceutical landscape.

Market Expansion and Geographic Focus

While specific data on AbbVie's geographic focus in endocrinology isn't provided, the company's global presence suggests a strategy of market expansion. Emerging markets, particularly in Asia-Pacific, present significant growth opportunities in the endocrinology sector.

Digital Transformation and Technology Integration

AbbVie is embracing digital transformation to enhance its competitive position. While specific details of its digital strategy in endocrinology aren't available, the company's overall focus on leveraging technology for innovation and operational efficiency is likely to benefit its endocrinology segment as well.

Challenges and Opportunities in the Endocrinology Market

Patent Expirations and Generic Competition

Like many pharmaceutical companies, AbbVie faces challenges related to patent expirations and increasing competition from generic drugs. This is particularly relevant in the endocrinology sector, where established treatments may face pricing pressures from biosimilars and generics.

Regulatory Environment

The pharmaceutical industry, including the endocrinology segment, operates in a highly regulated environment. AbbVie must navigate complex regulatory landscapes across different markets, which can impact product approvals, pricing, and market access.

Emerging Therapeutic Areas

The endocrinology field is witnessing advancements in areas such as diabetes management, thyroid disorders, and growth hormone therapies. These emerging therapeutic areas present both opportunities and challenges for AbbVie as it seeks to maintain and expand its market position.

AbbVie's Financial Performance and Market Valuation

While specific financial data for AbbVie's endocrinology segment isn't provided, the company's overall financial health is strong. AbbVie's diverse portfolio and strategic acquisitions have contributed to its robust financial performance, providing a solid foundation for investments in endocrinology and other therapeutic areas.

Future Outlook and Growth Projections

The endocrinology drugs market is poised for significant growth, with projections indicating a market value of USD 78.0 billion by 2033[1]. AbbVie's position in this growing market will depend on its ability to innovate, navigate regulatory challenges, and effectively compete with other major players in the field.

Comparative Analysis with Key Competitors

While detailed competitor data isn't available, it's worth noting that AbbVie operates in a highly competitive landscape. Companies like Novo Nordisk, Eli Lilly, and Sanofi are major players in the endocrinology market, each with their own strengths and market positions. AbbVie's success will depend on its ability to differentiate its offerings and capitalize on its unique strengths in research, development, and global market presence.

ESG Considerations in AbbVie's Strategy

Environmental, Social, and Governance (ESG) factors are increasingly important in the pharmaceutical industry. AbbVie's 2023 ESG Action Report highlights the company's commitment to delivering innovative medicines, fostering diversity and inclusion, and advancing long-term patient health[6]. These initiatives likely extend to the company's endocrinology segment, potentially influencing its market position and stakeholder perceptions.

Key Takeaways

  • AbbVie is well-positioned in the growing endocrinology drugs market, which is projected to reach USD 78.0 billion by 2033.
  • The company's strengths include a robust product portfolio, significant R&D investments, and strategic acquisitions.
  • AbbVie faces challenges from patent expirations, regulatory complexities, and intense competition in the endocrinology sector.
  • Future success will depend on continued innovation, effective market expansion, and the ability to navigate the evolving healthcare landscape.
  • ESG considerations are becoming increasingly important in shaping AbbVie's strategy and market perception.

FAQs

  1. Q: What is AbbVie's main focus in the endocrinology drugs market? A: While specific details aren't provided, AbbVie's focus likely includes developing innovative treatments for various endocrine disorders, leveraging its strong R&D capabilities and diverse product portfolio.

  2. Q: How does AbbVie's global presence impact its position in the endocrinology market? A: AbbVie's global footprint allows it to tap into diverse markets, adapt to regional healthcare needs, and potentially gain a competitive advantage in the endocrinology sector.

  3. Q: What are the main challenges AbbVie faces in the endocrinology drugs market? A: Key challenges include patent expirations, increasing competition from generics and biosimilars, complex regulatory environments, and the need for continuous innovation.

  4. Q: How is AbbVie addressing the digital transformation in healthcare? A: While specific details for endocrinology aren't provided, AbbVie is likely integrating digital technologies into its overall strategy to enhance drug development, improve patient outcomes, and optimize operations.

  5. Q: What role does ESG play in AbbVie's endocrinology strategy? A: AbbVie's ESG initiatives, focusing on innovative medicines, diversity, and long-term patient health, likely extend to its endocrinology segment, influencing its market approach and stakeholder relationships.

Sources cited: [1] https://market.us/report/endocrinology-drugs-market/ [6] https://www.abbvie.com/content/dam/abbvie-com2/pdfs/abbvie-esg-action-report.pdf

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.